Global Blood Therapeutics Inc (NASDAQ:GBT) – Research analysts at Oppenheimer issued their FY2022 EPS estimates for Global Blood Therapeutics in a report issued on Thursday. Oppenheimer analyst M. Breidenbach anticipates that the company will earn $4.30 per share for the year. Oppenheimer currently has a “Buy” rating and a $79.00 target price on the stock.
Global Blood Therapeutics (NASDAQ:GBT) last announced its quarterly earnings data on Thursday, November 2nd. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.04). During the same period in the prior year, the firm earned ($0.58) earnings per share.
Global Blood Therapeutics (GBT) traded up $0.15 during mid-day trading on Friday, reaching $56.60. The company’s stock had a trading volume of 968,595 shares, compared to its average volume of 1,600,000. The stock has a market cap of $2,600.00 and a price-to-earnings ratio of -22.20. Global Blood Therapeutics has a 1-year low of $14.70 and a 1-year high of $57.75.
Institutional investors and hedge funds have recently modified their holdings of the company. BNP Paribas Arbitrage SA increased its position in Global Blood Therapeutics by 694.9% in the second quarter. BNP Paribas Arbitrage SA now owns 4,547 shares of the company’s stock worth $124,000 after buying an additional 3,975 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of Global Blood Therapeutics in the 3rd quarter valued at approximately $200,000. Trexquant Investment LP bought a new stake in shares of Global Blood Therapeutics in the 3rd quarter valued at approximately $202,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Global Blood Therapeutics in the 3rd quarter valued at approximately $205,000. Finally, Virtu KCG Holdings LLC bought a new stake in shares of Global Blood Therapeutics in the 2nd quarter valued at approximately $219,000. Hedge funds and other institutional investors own 85.72% of the company’s stock.
In other news, VP Peter Radovich sold 12,500 shares of Global Blood Therapeutics stock in a transaction dated Monday, October 30th. The stock was sold at an average price of $35.00, for a total transaction of $437,500.00. Following the completion of the sale, the vice president now owns 2,684 shares in the company, valued at approximately $93,940. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Charles J. Homcy sold 70,000 shares of Global Blood Therapeutics stock in a transaction dated Friday, October 27th. The shares were sold at an average price of $33.97, for a total value of $2,377,900.00. Following the sale, the director now owns 83,328 shares of the company’s stock, valued at approximately $2,830,652.16. The disclosure for this sale can be found here. In the last quarter, insiders have sold 103,500 shares of company stock valued at $3,773,000. Corporate insiders own 5.30% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Markets Daily and is the property of of Markets Daily. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://www.themarketsdaily.com/2018/01/13/global-blood-therapeutics-inc-expected-to-earn-fy2022-earnings-of-4-30-per-share-gbt.html.
Global Blood Therapeutics Company Profile
Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.